NYSE American - Nasdaq Real Time Price USD

China Pharma Holdings, Inc. (CPHI)

0.3131 -0.0129 (-3.96%)
As of 2:15 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Zhilin Li President, CEO, Chairman & Interim CFO 241.6k -- 1953
Ms. Huang Na C.F.A. BOD Secretary & IR Manager -- -- --

China Pharma Holdings, Inc.

No. 17, Jinpan Road
Second Floor
Haikou, 570216
China
86 89 8668 11730 https://www.chinapharmaholdings.com
Sector: 
Healthcare
Full Time Employees: 
231

Description

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. The company also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. The company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Corporate Governance

China Pharma Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Apr 01, 2024
    10-K: Periodic Financial Reports
    See Full Filing
  • Mar 29, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Feb 23, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Feb 14, 2024
    CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
    See Full Filing
  • Feb 08, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing

Upcoming Events

Related Tickers